Ying-Chun ShenCHIUN HSUChen J.-Y.ANN-LII CHENG2021-03-092021-03-0920040007-0920https://www.scopus.com/inward/record.uri?eid=2-s2.0-7944226111&doi=10.1038%2fsj.bjc.6602200&partnerID=40&md5=cb95fed136e79d5736c4a616b88d49cehttps://scholars.lib.ntu.edu.tw/handle/123456789/551213Although the PPARγ agonist troglitazone has been shown to induce growth inhibition of hepatocellular carcinoma (HCC) cells at high concentration, this study indicates troglitazone does not significantly inhibit the growth of HCC cells at clinically achievable concentrations (1-10 μM), and this lack of activity could not be improved by the addition of 9-cis-retinoic acid. Furthermore, no synergistic effect was found between troglitazone and cytotoxic anticancer agents. ? 2004 Cancer Research UK.[SDGs]SDG3alitretinoin; cisplatin; cytotoxic agent; gemcitabine; irinotecan; paclitaxel; peroxisome proliferator activated receptor; retinoid X receptor alpha; troglitazone; 2,4 thiazolidinedione derivative; antineoplastic agent; chroman derivative; retinoic acid; troglitazone; article; cancer cell culture; cancer inhibition; cytotoxicity; drug efficacy; human; human cell; liver cell carcinoma; priority journal; protein expression; apoptosis; cell culture; cell division; comparative study; dose response; drug effect; drug potentiation; liver tumor; metabolism; pathology; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Division; Chromans; Dose-Response Relationship, Drug; Drug Synergism; Humans; Liver Neoplasms; Thiazolidinediones; Tretinoin; Tumor Cells, Culturedjournal article10.1038/sj.bjc.6602200154677642-s2.0-7944226111